NEW YORK (GenomeWeb News) – Atossa Genetics reported after the close of the market on Thursday $105,576 in revenues for the third quarter compared to no revenues in the year-ago period.

For the three months ended Sept. 30, revenues were comprised of $104,011 in Diagnostic Testing Services and $1,565 in product sales. The Seattle-based firm launched ForeCYTE and ArgusCYTE tests a year ago and said today that it expects to roll out the tests nationally in early 2013.

Atossa said that its SG&A spending retreated 3 percent to $1.23 million from $1.27 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.